Sugi Predict

Sugi Predict / Compounds / SCHEMBL1220143

SCHEMBL1220143

SCHEMBL1220143

CC1(C)CC(=O)c2c(C(F)(F)F)n[nH]c2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.56
▸ ALPL P05186 8/20 0.54
▸ ALDH1A1 P00352 2/20 0.51
▸ HPGD P15428 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ OPRM1 P35372 1/20 0.38
▸ GSK3A P49840 4/20 0.36
▸ TSHR P16473 1/20 0.36
▸ BUB1 O43683 3/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ HDAC9 Q9UKV0 1/20 0.35
▸ HDAC5 Q9UQL6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7482231 0.85 HSD17B10 (0.58) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL460286 0.76 HSD17B10 (0.63) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL10123130 0.75 HSD17B10 (0.61) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL25189591 0.74 DHODH (0.41) TSHR
SCHEMBL13343014 0.72 HSD17B10 (0.58) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL382806 0.71 DHODH (0.52) KMT2ATSHR
SCHEMBL19398370 0.69 HSD17B10 (0.70) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL3630522 0.68 BUB1 (0.40) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL7479968 0.67 ALPL (0.73) HSD17B10ALPLALDH1A1HPGDCYP3A4
SCHEMBL15723771 0.65 OPRM1 (0.52) HSD17B10ALPLALDH1A1KMT2AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124460-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) 2024-04-18 — — US disclosed
CN-117820416-A Hsp90PROTAC compound, preparation method thereof and application thereof in preparation of anti-cervical cancer drugs 武汉大学 2024-04-05 — — CN disclosed
US-20230391792-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) 2023-12-07 — — US disclosed
US-20230391772-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) 2023-12-07 — — US disclosed
EP-4229061-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) 2023-08-23 — — EP disclosed
EP-4228700-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) 2023-08-23 — — EP disclosed
EP-4229053-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) 2023-08-23 — — EP disclosed
CN-116615429-A Methods and compositions for targeting protein degradation 珃诺生物医药科技(杭州)有限公司 2023-08-18 — — CN disclosed
CN-116615422-A Methods and compositions for targeting protein degradation 珃诺生物医药科技(杭州)有限公司 2023-08-18 — — CN disclosed
CN-116507368-A Methods and compositions for targeting protein degradation 珃诺生物医药科技(杭州)有限公司 2023-07-28 — — CN disclosed
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2008-04-24 — — US disclosed
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2008-04-24 — — US disclosed
US-7358370-B2 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide SERENEX, INC. (US) 2008-04-15 — — US disclosed
US-7358370-B2 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide SERENEX, INC. (US) 2008-04-15 — — US disclosed
US-7358370-B2 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide SERENEX, INC. (US) 2008-04-15 — — US disclosed
US-20080070935-A1 Isoquinoline, Quinazoline and Phthalazine Derivatives ESANEX, INC. 2008-03-20 — — US disclosed
WO-2008024977-A2 ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES SERENEX, INC. (US) 2008-02-28 — — WO disclosed
EP-1856057-A1 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES Serenex, Inc. (US) 2007-11-21 — — EP disclosed
US-20060211737-A1 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide ESANEX, INC. 2006-09-21 — — US disclosed
WO-2006091963-A1 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2006-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391792-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION PSMG3, PSMC2, PSMB11 HSD17B10 2565/4885ALPL 2336/4885ALDH1A1 3874/4885
US-20240124460-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION PSMG3, PSMC2, PSMA6 HSD17B10 3431/4885ALPL 3349/4885ALDH1A1 3527/4885
US-20080070935-A1 Isoquinoline, Quinazoline and Phthalazine Derivatives H1-5, NDUFS5, IL5 HSD17B10 3696/4885ALPL 589/4885ALDH1A1 1920/4885
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor HSP90AA1, HSP90AB1, HSPA4 HSD17B10 1430/4885ALPL 4136/4885ALDH1A1 2373/4885
US-20060211737-A1 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide HSF1, HSPA4, HSP90AB1 HSD17B10 4158/4885ALPL 4849/4885ALDH1A1 1756/4885
US-20230391772-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION PSMG3, PSMC2, PSMA6 HSD17B10 3431/4885ALPL 3349/4885ALDH1A1 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.